Research Signal – Source date 2026-08-21
Agitation, wandering, hallucinations, aggression, sleep disruption, and other behavioral symptoms can make hospitalization especially difficult for older adults with dementia or delirium. They can also complicate care for families and hospital staff. A study in Italy is testing whether adding structured, individualized activities and caregiver teaching to usual medication management can reduce those symptoms before discharge.
The study is called ESSECOA. It is a single-center randomized trial in the Geriatric Unit of the Azienda Ospedaliero-Universitaria di Modena. The supplied ClinicalTrials.gov record describes the trial’s design and planned comparisons, but has no posted results. The central question is therefore how the study is set up to test the approach, not whether patients have already been shown to improve.
The trial adds a care package to usual treatment
Participants are adults over 65 who are hospitalized with dementia, delirium, or both. The registry lists actual enrollment of 132 people. Participants are randomly assigned to one of two parallel groups, which gives the comparison a defined structure: both groups receive pharmacological management, while only one receives the additional psychosocial program.
The comparison group receives medication management according to applicable clinical guidelines or, where specific guidance is unavailable, best clinical practice. The treating physician individualizes that management according to the patient’s symptoms, clinical condition, and other health problems. The protocol does not require one particular drug, dose, or fixed medication regimen.
The other group receives the same medication-based care plus individualized sensory and general stimulation. Caregivers take part in the stimulation sessions and receive two structured educational sessions, one during hospitalization and another before discharge. The study is therefore testing a combined care package rather than a single isolated activity.
That detail matters when interpreting any eventual difference between the groups. If the added-care group has better symptom scores, the trial would show the value of the package as delivered, including staff-led activities and caregiver education together. It would not, by itself, reveal how much of any change came from stimulation, family participation, or the teaching sessions separately.
A session is built around the person
The intervention is scheduled three times per week during the hospital stay, with each session lasting about 40 minutes. Trained staff in the geriatric unit tailor the activities to the patient’s personal history, preferences, target symptoms, and remaining abilities. The registry describes possible activities involving the senses and simple meaningful tasks, including multisensory stimulation in a Snoezelen environment.
This personalization is more specific than simply offering patients a generic pastime. A person’s previous interests, current behavioral symptoms, and ability to participate help determine what the staff use during the session. The practical goal being tested is a repeatable way for hospital staff to provide individualized stimulation within acute care, where routines, illness, and limited time can make such care difficult to organize.
Caregiver involvement extends beyond observing a session. Family members participate during the stimulation and receive teaching about communication and individualized ways to manage behavioral symptoms at home. The registry frames those strategies as something caregivers may continue using after discharge, but the trial’s main symptom comparison takes place before or at discharge.
The main test is a change in symptom score
Researchers use the Neuropsychiatric Inventory, or NPI, to assess behavioral and psychological symptoms in participants with dementia and/or delirium. The primary outcome is the change in the total NPI score from the baseline assessment to the pre-discharge assessment, within a hospital stay of up to 45 days. Higher scores indicate more severe symptoms.
The investigators plan to compare the average change between the two randomized groups. The registry defines a between-group difference of at least 10 points as clinically relevant. That threshold describes how the study will judge the size of a meaningful difference; it is not evidence that such a difference occurred.
The study also examines changes in individual NPI domains. This could show whether some types of behavioral symptoms respond differently from others, rather than reducing the result to one total score. Additional assessments listed in the record include delirium, cognitive and functional status, depression, comorbidity, antipsychotic medication use, length of stay, discharge destination, healthcare use, mortality, caregiver burden, perceived competence, and perceived needs. Their inclusion means the researchers are collecting a broader picture of the hospitalization, not that the intervention has already changed any of these outcomes.
What the registry can tell us so far
The record lists an actual study start date of September 1, 2021. It lists primary completion as August 6, 2026, an actual date, and overall completion as August 30, 2026, an estimated date. The study is listed as active, not recruiting. These are lifecycle details about the registered study, not outcome findings.
The randomized parallel-group design can help compare the added care package with usual treatment in this hospital setting. Its open-label structure also matters: participants and care staff know which care they receive, and the supplied evidence does not establish whether outcome assessors were masked. The record provided here also does not supply a statistical analysis plan or additional follow-up details.
The setting narrows how far any result could travel. A single geriatric unit may have staff skills, space, routines, and caregiver participation patterns that are not reproduced in other hospitals. Even a favorable discharge result would describe symptom change during one hospitalization. It would not establish durable benefit at home, effectiveness in other institutions, or reductions in falls, hospital stay, mortality, institutionalization, antipsychotic use, or caregiver burden.
Most importantly, the available material contains no outcome estimates establishing improvement, safety, or superiority over standard management. It identifies a carefully defined question and a way to compare two treatment packages. The evidence needed to answer that question was not yet posted in the supplied registry snapshot.
What this could mean for hospital care
If the combined approach produces a clinically meaningful improvement in behavioral symptoms and hospitals can deliver it consistently, it could give care teams a structured way to ease distress while treating patients as individuals rather than responding only to the most difficult behavior in the moment. The caregiver sessions could also make communication and management strategies part of the transition home.
Patients could benefit from better symptom management, and caregivers could leave with clearer ways to communicate and respond, provided the full package demonstrates benefit and can be delivered reliably in hospital practice. Improved outcomes after discharge would remain a further possibility requiring evidence.
Key Sources
- Primary source: Psychosocial Intervention for Behavioral Symptoms in Hospitalized Patients With Dementia or Delirium
Government or Regulator · Clinical Trial · 2026-08-21
Keep exploring